Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 1, 2001, Pages 42-47

  Wang, Jiu Hui ^a   Liu, Zhao Qian ^a   Wang, Wei ^a   Chen, Xiao Ping ^a   Shu, Yan ^a   He, Nan ^a   Zhou, Hong Hao ^a  

^a Hunan Medical University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; DIAZEPAM; NORSERTRALINE; OMEPRAZOLE; SERTRALINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMETHYLATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ELECTRON CAPTURE DETECTION; ENZYME BINDING; GAS CHROMATOGRAPHY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADMINISTRATION, ORAL; ADULT; ANTIDEPRESSIVE AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHROMATOGRAPHY, GAS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; PHENOTYPE; POLYMORPHISM, GENETIC; REFERENCE VALUES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TIME FACTORS;

EID: 0034923234     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.116513     Document Type: Article

References (25)

1. Pharmacology of sertraline: A review
2. Sertraline, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depression and obsessive-compulsive disorder
3. Pharmacokinetics of selective serotonin reuptake inhibitors
4. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro
5. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes
6. The disposition of fluoxetine but not sertraline is altered in PMs of debrisoquin
7. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans
8. A novel defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
9. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese
10. The molecular genetics of the P450 subfamily
11. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin
12. Sertraline in the treatment of major depression: An open clinical stratification study in Italian outpatients
13. Toleration and safety of sertraline: Experience worldwide
14. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study
15. Automated gas chromato-graphic - Electron-capture assay for the selective serotonin uptake blocker sertraline
16. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylation of debrisoquin and S-mephenytoin
17. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele
18. Pharmacogenetics' of mephenytoin: A new drug hydroxylation polymorphism in man
19. Metoprolol and mephenytoin oxidation polymorphism in far eastern Oriental subjects: Japanese versus mainland Chinese
20. Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog
21. Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population
22. The effect of gene dose on the activity of S-mephenytoin hydroxylase
23. The induction effect of rifampicin on activity of mephenytoin 4 hydroxylase related to M1 mutation of CYP2C19 and gene dose
24. Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects
25. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression